Drug Approval | March 06, 2022
USFDA approves expanded use of Bristol Myers Opdivo
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
The guidance also urges companies to act quickly to initiate a recall when public health is at risk and to do so prior to completing an investigation into the cause of the problem
Covaxin is not approved in the USA for any age group
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
This ninth update of WHO’s guideline on therapeutics includes a recommendation that casirivimab-imdevimab not be used for patients infected with the Omicron variant
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
Subscribe To Our Newsletter & Stay Updated
